Elicio Therapeutics Inc. (ELTX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.68 (-4.00% 1D, market cap $45.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ELTX ranks #867 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and BMEA (Biomea Fusion Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while DWTX leads on capital efficiency (-32.3% ROIC).
Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $0 in revenue, -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ELTX currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.01) and Max Pain ($1.76) forces dealer call-delta covering toward $16.80.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Elicio Therapeutics Inc. (ELTX) dropped -4.00% to $1.68, trading at 2% of its 52-week range ($1.44 – $16). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the
Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in both ctDNA-negative (HR
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Elicio Therapeutics Inc. (ELTX) ranks #867 by composite RQD confidence (28/100, grade E) and #760 by equity capitalization ($45.5M). Within this direct 5-issuer industry benchmark cohort, ELTX leads on earnings valuation at N/A trailing P/E, while DWTX leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ATNM currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ELTX at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELTX
ACTIVE
Elicio Therapeutics Inc. | E | 28/100 | — | — | -35.0% | -4.00% | $45.5M | Benchmark Subject |
| MREO Mereo BioPharma Group plc | D- | 37/100 | — | — | -35.0% | -4.08% | $46.2M | /mreo-vs-eltx → |
| BMEA Biomea Fusion Inc. | E | 30/100 | — | — | -35.0% | +2.68% | $46.4M | /bmea-vs-eltx → |
| ATNM Actinium Pharmaceuticals Inc. (Delaware) | D- | 43/100 | — | — | -35.0% | -3.27% | $46.5M | /atnm-vs-eltx → |
| DWTX Dogwood Therapeutics Inc. | D- | 38/100 | — | — | -32.3% | +4.07% | $43.5M | /dwtx-vs-eltx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elicio Therapeutics Inc. (ELTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.6M, operating cash flow of -$37.0M, and free cash flow of -$37.0M (+0.5% YoY). On the balance sheet, ELTX closed FY2025 with $25.9M in total assets against $9.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$39.6M | -$37.0M | -$37.0M | $25.9M | $9.4M |
| FY2024 (FY) | 2024-12-31 | $0 | -$51.9M | -$37.1M | -$37.2M | $28.2M | $20.0M |
| FY2023 (FY) | 2023-12-31 | $0 | -$35.2M | -$32.7M | -$32.7M | — | — |
As of 2026-11-03, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.68 (-4.00% 1D, market cap $45.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ELTX ranks #867 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and BMEA (Biomea Fusion Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while DWTX leads on capital efficiency (-32.3% ROIC).
Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $0 in revenue, -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ELTX last traded at $1.68 (-4.00% on volume of 183,894 shares), positioning the stock -16.42% below its 50-day simple moving average ($2.01) and -75.00% below its 200-day simple moving average ($6.72). Across its 52-week range of $1.44 to $16.00, ELTX sits at the 1.6% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.47 to $1.89).
Why ELTX Stock dropped -4.00% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ELTX scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 5.75). Taken together, the weakest pillars are the cash engine and the smart-money signals, both of which sit at or near the bottom of their ranges. For a prospective investor, the implication is that the stock currently lacks internal cash generation, and the rating's inputs do not offer strong external validation to offset that. The forensic balance-sheet reading, while still weak, is the least negative of the five, which suggests the risk profile is driven more by operating burn than by leverage alone. Any upside case would need to rest on events outside the financial statements, such as clinical or regulatory developments, rather than on improving fundamentals visible in this data.
Elicio Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is classified in this industry, though the source data does not describe its specific products, customers, or revenue model. Reported revenue for FY 2025 and FY 2024 is $0.0M in each period per the SEC financials, indicating no reported revenue in those years. Not available in source data for how the company monetizes its activities.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-37.7M | $-39.6M | N/A | $-37.0M | $18.6M | $9.4M |
| FY 2024 | $0.0M | $-45.0M | $-51.9M | N/A | $-37.2M | $17.6M | $20.0M |
| FY 2023 | $0.0M | $-35.7M | $-35.2M | N/A | $-32.7M | N/A | N/A |
Per the SEC financials, the company reported operating losses in all three periods, with gross, operating, and net margins each at 0% per the market data. ROIC is -35% per the market data and FCF yield is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 5.75. Cash declined from $17.6M to $18.6M between periods only in the sense that FY 2025 is reported higher than FY 2024; debt fell from $20.0M to $9.4M across the same span. The balance sheet therefore shows reduced leverage alongside continued cash-consuming operations.
Per the recent news feed, the most prominent items are as follows:
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The clinical presentations are the primary catalysts; the price-move items are market commentary. Risk watch items include the 52-week range of $1.44 to $16, indicating a large drawdown, and the price move of -5.4% in the latest session per the market data.
Real-time company headlines, analyst actions, and sector developments for Elicio Therapeutics Inc. (ELTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the
Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in both ctDNA-negative (HR
Welcome to the ELTX (Elicio Therapeutics Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ELTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Elicio Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ELTX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.75 (52-wk range $1.44 - $16.00), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).